Pub Date : 2024-01-31DOI: 10.1186/s12645-024-00247-5
Xinyan Lu, Peng Zhang, Jun Li, Yi Zhou, Bangjun Wang, Zhaoli Lu
The research aims to observe the difference in the effect of preoperative doxorubicin curcumin co-loaded lipid nanoparticles (DOX+CUR LPNs) and doxorubicin (VAD) in the treatment of osteosarcoma. 68 patients with osteosarcoma who visited the hospital from January 2020 to December 2022 are chosen. They are separated into VAD group and DOX+CUR LPNs group, with 34 cases in each group. VAD and DOX+CUR LPNs groups VAD chemotherapy, and DOX+CUR LPNs treatment, respectively. All patients receive tumor resection. Comparison is made between the two groups before chemotherapy, at the end of chemotherapy and 1 week after surgery on the changes of vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang-2), galectin-3 (Gal-3), renal function indicators cystatin-C (Cys-C), serum creatinine (Scr), blood urea nitrogen (BUN) in the peripheral blood. The clinical efficacy and adverse reactions are determined by observation and follow-up for 1 month. The VEGF, Ang-2, and Gal-3 in both groups were significantly lower at 1 week after chemotherapy and surgery compared to before chemotherapy (P < 0.05). The VEGF and Gal-3 in the DOX+CUR LPNs group were lower than those in the VAD group in the same period, with P < 0.05. The Cys-C, Scr, and BUN in both groups of patients after chemotherapy and surgery increased compared to before chemotherapy, with P < 0.05. The Cys-C, Scr, and BUN in the DOX+CUR LPNs group were lower than those in the VAD group during the same period, with P < 0.05. Following up for 1 month, the ORR of the DOX+CUR LPNs group was 94.12% (32/34) higher than that of the VAD group, with P < 0.05. The incidence of adverse reactions in the DOX+CUR LPNs group was 47.05% lower than that in the VAD group, with P < 0.05. Preoperative application of DOX+CUR LPNs enables effective drug delivery to the tumor section by combining the antibacterial, antioxidant and anti-inflammatory effects of curcumin, which is co-wrapped in nanoparticles. It has the effect of promoting angiogenesis and damage repair, inhibiting inflammation-related factors, and protecting renal function, while adriamycin alone has drug resistance problems and toxic side effects, which can damage the patient's liver and kidney. Therefore, DOX+CUR LPNs are more effective than adriamycin alone, indicating that it can improve the therapeutic effect of the drug and reduce the side effects, which is of great significance for improving the survival rate and quality of life of patients.
研究旨在观察术前多柔比星姜黄素联合负载脂质纳米颗粒（DOX+CUR LPNs）与多柔比星（VAD）治疗骨肉瘤的效果差异。选取2020年1月至2022年12月在医院就诊的68名骨肉瘤患者。分为VAD组和DOX+CUR LPNs组，每组34例。VAD组和DOX+CUR LPNs组分别采用VAD化疗和DOX+CUR LPNs治疗。所有患者均接受肿瘤切除术。比较两组患者化疗前、化疗结束时和术后 1 周外周血中血管内皮生长因子（VEGF）、血管生成素-2（Ang-2）、凝血酶原-3（Gal-3）、肾功能指标胱抑素-C（Cys-C）、血清肌酐（Scr）、血尿素氮（BUN）的变化。临床疗效和不良反应通过为期 1 个月的观察和随访确定。与化疗前相比，两组患者化疗和手术后1周的VEGF、Ang-2和Gal-3均明显降低（P＜0.05）。DOX+CUR LPNs组的VEGF和Gal-3低于同期的VAD组，P＜0.05。两组患者化疗和手术后的 Cys-C、Scr 和 BUN 均比化疗前升高，P＜0.05。DOX+CUR LPNs 组的 Cys-C、Scr 和 BUN 均低于同期的 VAD 组，P＜0.05。随访1个月，DOX+CUR LPNs组的ORR为94.12%（32/34），高于VAD组，P＜0.05。DOX+CUR LPNs 组的不良反应发生率比 VAD 组低 47.05%，P<0.05。术前应用DOX+CUR LPNs可将姜黄素的抗菌、抗氧化和抗炎作用结合在一起，并将其包裹在纳米颗粒中，从而实现对肿瘤切片的有效给药。它具有促进血管生成和损伤修复、抑制炎症相关因子、保护肾功能等作用，而单独使用阿霉素存在耐药性问题和毒副作用，会损害患者的肝脏和肾脏。因此，DOX+CUR LPNs 比单用阿霉素更有效，说明它能提高药物的治疗效果，减少副作用，对提高患者的生存率和生活质量具有重要意义。
{"title":"The effect of doxorubicin curcumin co-loaded lipid nanoparticles and doxorubicin on osteosarcoma before surgery","authors":"Xinyan Lu, Peng Zhang, Jun Li, Yi Zhou, Bangjun Wang, Zhaoli Lu","doi":"10.1186/s12645-024-00247-5","DOIUrl":"https://doi.org/10.1186/s12645-024-00247-5","url":null,"abstract":"The research aims to observe the difference in the effect of preoperative doxorubicin curcumin co-loaded lipid nanoparticles (DOX+CUR LPNs) and doxorubicin (VAD) in the treatment of osteosarcoma. 68 patients with osteosarcoma who visited the hospital from January 2020 to December 2022 are chosen. They are separated into VAD group and DOX+CUR LPNs group, with 34 cases in each group. VAD and DOX+CUR LPNs groups VAD chemotherapy, and DOX+CUR LPNs treatment, respectively. All patients receive tumor resection. Comparison is made between the two groups before chemotherapy, at the end of chemotherapy and 1 week after surgery on the changes of vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang-2), galectin-3 (Gal-3), renal function indicators cystatin-C (Cys-C), serum creatinine (Scr), blood urea nitrogen (BUN) in the peripheral blood. The clinical efficacy and adverse reactions are determined by observation and follow-up for 1 month. The VEGF, Ang-2, and Gal-3 in both groups were significantly lower at 1 week after chemotherapy and surgery compared to before chemotherapy (P < 0.05). The VEGF and Gal-3 in the DOX+CUR LPNs group were lower than those in the VAD group in the same period, with P < 0.05. The Cys-C, Scr, and BUN in both groups of patients after chemotherapy and surgery increased compared to before chemotherapy, with P < 0.05. The Cys-C, Scr, and BUN in the DOX+CUR LPNs group were lower than those in the VAD group during the same period, with P < 0.05. Following up for 1 month, the ORR of the DOX+CUR LPNs group was 94.12% (32/34) higher than that of the VAD group, with P < 0.05. The incidence of adverse reactions in the DOX+CUR LPNs group was 47.05% lower than that in the VAD group, with P < 0.05. Preoperative application of DOX+CUR LPNs enables effective drug delivery to the tumor section by combining the antibacterial, antioxidant and anti-inflammatory effects of curcumin, which is co-wrapped in nanoparticles. It has the effect of promoting angiogenesis and damage repair, inhibiting inflammation-related factors, and protecting renal function, while adriamycin alone has drug resistance problems and toxic side effects, which can damage the patient's liver and kidney. Therefore, DOX+CUR LPNs are more effective than adriamycin alone, indicating that it can improve the therapeutic effect of the drug and reduce the side effects, which is of great significance for improving the survival rate and quality of life of patients.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"290 1 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139648895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The present study proposed to design nanostructured lipid carriers (NLC) coated with chitosan (CS) conjugated folate (FA) for the targeted delivery of Osthole (OST) to the HT-29 colon cancer cell line and improve its anticancer capability. To assess the physicochemical characteristics of OST-loaded NLC decorated with CS-conjugated FA (OST-NCF-NPS), several techniques, including DLS, SEM, and FTIR, were applied. After determining the encapsulation efficiency of OST in CSFA-modified NLC-NPs, an MTT test was conducted to evaluate the cytotoxic effects of this nano platform on the HT-29 cancer cell line in comparison to normal HFF cells. Possible mechanisms of apoptosis in cancer cells treated with OST-NCF-NPs were examined using qPCR, flow cytometry, and AO/PI fluorescent staining methods. Moreover, the antioxidant capacity of these biosynthesized nanocarriers was determined using ABTS and DPPH methods, and their antibacterial potential was measured through disk diffusion, MIC, and MBC assays. According to the findings, OST-NCF-NPS had the ideal average size of 179.19 nm, low polydispersity (PI = 0.23), acceptable physical stability (ζ-potential = + 18.99 mV), and high entrapment efficiency (83.5%). The MTT data demonstrated the selective cytotoxicity of NPs toward cancerous cells compared to normal cells. Cell cycle and Annexin V/Propidium Iodide (AnV/PI) analysis indicated that OST-NCF-NPs increased the sub-G1 population and AnV/PI-positive cells. The occurrence of programmed cell death in the treated cells was also verified by altered expression of proapoptotic (BAX and caspase-3) and antiapoptotic (Bcl-2) genes. Furthermore, the NPs exhibited strong antibacterial activity, particularly against gram-negative bacteria, and high antioxidant effects in reducing ABTS and DPPH-free radicals.
{"title":"Designing nanostructured lipid carriers modified with folate-conjugated chitosan for targeted delivery of osthole to HT-29 colon cancer cells: investigation of anticancer, antioxidant, and antibacterial activities","authors":"Ghazal Hosseini Torshizi, Masoud Homayouni Tabrizi, Ehsan Karimi, Atefeh Younesi, Zahra Larian","doi":"10.1186/s12645-024-00246-6","DOIUrl":"https://doi.org/10.1186/s12645-024-00246-6","url":null,"abstract":"The present study proposed to design nanostructured lipid carriers (NLC) coated with chitosan (CS) conjugated folate (FA) for the targeted delivery of Osthole (OST) to the HT-29 colon cancer cell line and improve its anticancer capability. To assess the physicochemical characteristics of OST-loaded NLC decorated with CS-conjugated FA (OST-NCF-NPS), several techniques, including DLS, SEM, and FTIR, were applied. After determining the encapsulation efficiency of OST in CSFA-modified NLC-NPs, an MTT test was conducted to evaluate the cytotoxic effects of this nano platform on the HT-29 cancer cell line in comparison to normal HFF cells. Possible mechanisms of apoptosis in cancer cells treated with OST-NCF-NPs were examined using qPCR, flow cytometry, and AO/PI fluorescent staining methods. Moreover, the antioxidant capacity of these biosynthesized nanocarriers was determined using ABTS and DPPH methods, and their antibacterial potential was measured through disk diffusion, MIC, and MBC assays. According to the findings, OST-NCF-NPS had the ideal average size of 179.19 nm, low polydispersity (PI = 0.23), acceptable physical stability (ζ-potential = + 18.99 mV), and high entrapment efficiency (83.5%). The MTT data demonstrated the selective cytotoxicity of NPs toward cancerous cells compared to normal cells. Cell cycle and Annexin V/Propidium Iodide (AnV/PI) analysis indicated that OST-NCF-NPs increased the sub-G1 population and AnV/PI-positive cells. The occurrence of programmed cell death in the treated cells was also verified by altered expression of proapoptotic (BAX and caspase-3) and antiapoptotic (Bcl-2) genes. Furthermore, the NPs exhibited strong antibacterial activity, particularly against gram-negative bacteria, and high antioxidant effects in reducing ABTS and DPPH-free radicals. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"45 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139556106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-23DOI: 10.1186/s12645-024-00245-7
Jie Sun, Zhengyao Chang, Xudong Gao, Huiwei Sun, Yantao Chai, Xiaojuan Li, Xiaoming Zhang, Fan Feng
Metallofullerenes are an important type of metallic nanomaterial with promising applications in several medical fields. Thermal ablation, including radiofrequency ablation (RFA) and microwave ablation (MWA), is an important treatment strategy for advanced hepatocellular carcinoma (HCC). The thermal expansion of fullerenes makes them good adjuncts to thermal ablation treatment of HCC. In this study, we used an innovative method of emulsification and cross-linking to produce CS-C60-Fe3O4 (Chitosan-C60-Fe3O4) nanoparticles, which have the advantages of uniform particle size and high bioavailability, as a kind of novel nano-pharmaceutical. The CS-C60-Fe3O4 nanoparticles were prepared by the cross-linking reaction from chitosan–acetic acid solution, Fe3O4 nanoparticles by Fe2SO4·7H2O and FeCl3·6H2O, and C60. The average particle size of CS-C60-Fe3O4 was 194.3 nm. Because CS-C60-Fe3O4 is magnetic, it can achieve specific and tissue aggregation in HCC tumor tissues. Moreover, compared with normal soluble C60 (EL35-C60), CS-C60-Fe3O4 prolonged the retention time of C60 in the blood of mice. CS-C60-Fe3O4 alone is not cytotoxic to cultured cells or tumor tissues, but when combined with thermal ablation strategies (RFA and MWA), it significantly upregulates the antitumor effects of thermal ablation on HCC tissues, that is, it acts as a sensitiser to thermal ablation. In the presence of thermal ablation, CS-C60-Fe3O4 interfered with iron metabolism in HCC cells and induced ferroptosis of HCC cells in the tumor tissues. These results not only expand our understanding of metallofullerenes but also provide additional options for the treatment of advanced HCC.
{"title":"Novel nanoparticle CS-C60-Fe3O4 magnetically induces tissue-specific aggregation and enhances thermal ablation of hepatocellular carcinoma","authors":"Jie Sun, Zhengyao Chang, Xudong Gao, Huiwei Sun, Yantao Chai, Xiaojuan Li, Xiaoming Zhang, Fan Feng","doi":"10.1186/s12645-024-00245-7","DOIUrl":"https://doi.org/10.1186/s12645-024-00245-7","url":null,"abstract":"Metallofullerenes are an important type of metallic nanomaterial with promising applications in several medical fields. Thermal ablation, including radiofrequency ablation (RFA) and microwave ablation (MWA), is an important treatment strategy for advanced hepatocellular carcinoma (HCC). The thermal expansion of fullerenes makes them good adjuncts to thermal ablation treatment of HCC. In this study, we used an innovative method of emulsification and cross-linking to produce CS-C60-Fe3O4 (Chitosan-C60-Fe3O4) nanoparticles, which have the advantages of uniform particle size and high bioavailability, as a kind of novel nano-pharmaceutical. The CS-C60-Fe3O4 nanoparticles were prepared by the cross-linking reaction from chitosan–acetic acid solution, Fe3O4 nanoparticles by Fe2SO4·7H2O and FeCl3·6H2O, and C60. The average particle size of CS-C60-Fe3O4 was 194.3 nm. Because CS-C60-Fe3O4 is magnetic, it can achieve specific and tissue aggregation in HCC tumor tissues. Moreover, compared with normal soluble C60 (EL35-C60), CS-C60-Fe3O4 prolonged the retention time of C60 in the blood of mice. CS-C60-Fe3O4 alone is not cytotoxic to cultured cells or tumor tissues, but when combined with thermal ablation strategies (RFA and MWA), it significantly upregulates the antitumor effects of thermal ablation on HCC tissues, that is, it acts as a sensitiser to thermal ablation. In the presence of thermal ablation, CS-C60-Fe3O4 interfered with iron metabolism in HCC cells and induced ferroptosis of HCC cells in the tumor tissues. These results not only expand our understanding of metallofullerenes but also provide additional options for the treatment of advanced HCC.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"30 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139556111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-13DOI: 10.1186/s12645-023-00244-0
Weidong Zhang, Liang Dai, Na Wang, Yunhe Liu, Zining Hao, Yaqian He, Song Ni, Yimin Wang, Dawei Gao
The poor targeting delivery efficiency and limited efficacy of single therapeutic approach have consistently posed significant challenges in tumor management. In this research, we have conceived and synthesized a dual-targeting nanodrug delivery system denoted as PDA-DEM-Fe3O4@M, which incorporates a polydopamine nanoparticle (PDA) with photothermal properties, diethyl maleate (DEM) as a chemotherapy agent accelerating tumor apoptosis, iron oxide nanoparticles (Fe3O4) eliciting magnetic targeting effects, and tumor cell membranes (M) contributing to homologous targeting capabilities. The synergistic effect of PDA-induced photothermal therapy and DEM-mediated chemotherapy has been demonstrated in this study to exert a robust inhibitory and cytotoxic influence on tumor cells. Additionally, the biocompatibility of this system has also been demonstrated. Through the synergistic effects of PDA’s photothermal therapy and DEM’s chemotherapy, this system demonstrated excellent inhibition and killing effects on tumor cells. Furthermore, we established its excellent biological safety profile. This study demonstrated the potential of this nanomaterial for clinical application in tumor therapy.
单一治疗方法靶向性差、疗效有限，一直是肿瘤治疗面临的重大挑战。在这项研究中，我们构思并合成了一种双靶向纳米药物递送系统，称为 PDA-DEM-Fe3O4@M ，它将具有光热特性的聚多巴胺纳米粒子（PDA）、可加速肿瘤细胞凋亡的化疗药物马来酸二乙酯（DEM）、可激发磁性靶向效应的氧化铁纳米粒子（Fe3O4）以及具有同源靶向能力的肿瘤细胞膜（M）结合在一起。本研究证明，PDA 诱导的光热疗法和 DEM 介导的化疗具有协同效应，可对肿瘤细胞产生强有力的抑制和细胞毒性影响。此外，该系统的生物相容性也得到了证实。通过 PDA 光热疗法和 DEM 化疗的协同作用，该系统对肿瘤细胞具有良好的抑制和杀伤作用。此外，我们还确定了其出色的生物安全性。这项研究证明了这种纳米材料在肿瘤治疗中的临床应用潜力。
{"title":"Dual-targeting nanomedicine achieves synergistic multimodal therapy for tumor","authors":"Weidong Zhang, Liang Dai, Na Wang, Yunhe Liu, Zining Hao, Yaqian He, Song Ni, Yimin Wang, Dawei Gao","doi":"10.1186/s12645-023-00244-0","DOIUrl":"https://doi.org/10.1186/s12645-023-00244-0","url":null,"abstract":"The poor targeting delivery efficiency and limited efficacy of single therapeutic approach have consistently posed significant challenges in tumor management. In this research, we have conceived and synthesized a dual-targeting nanodrug delivery system denoted as PDA-DEM-Fe3O4@M, which incorporates a polydopamine nanoparticle (PDA) with photothermal properties, diethyl maleate (DEM) as a chemotherapy agent accelerating tumor apoptosis, iron oxide nanoparticles (Fe3O4) eliciting magnetic targeting effects, and tumor cell membranes (M) contributing to homologous targeting capabilities. The synergistic effect of PDA-induced photothermal therapy and DEM-mediated chemotherapy has been demonstrated in this study to exert a robust inhibitory and cytotoxic influence on tumor cells. Additionally, the biocompatibility of this system has also been demonstrated. Through the synergistic effects of PDA’s photothermal therapy and DEM’s chemotherapy, this system demonstrated excellent inhibition and killing effects on tumor cells. Furthermore, we established its excellent biological safety profile. This study demonstrated the potential of this nanomaterial for clinical application in tumor therapy.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"41 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139459038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-10DOI: 10.1186/s12645-023-00242-2
Valentina Coccè, Eleonora Martegani, Luisa Doneda, Isabella Rimoldi, Giorgio Facchetti, Coffetti Giulia, Giorgio Lucchini, Leda Roncoroni, Aldo Giannì, Costantino Corradini, Giulio Alessandri, Emilio Ciusani, Francesco Cilurzo, Silvia Franzè, Francesca Paino, Augusto Pessina
Glioblastoma multiforme (GBM) is nowadays the most aggressive tumor affecting brain in adults with a very poor prognosis due to the limited therapies and the systemic cytotoxicity. Among the different new drugs, recently has been reported the in vitro anti-glioma activity of a new cationic platinum(II) complex bearing 8-aminoquinoline as chelating ligand (Pt-8AQ). The purpose of this research work was to confirm the activity of Pt-8AQ on U87-GM spheroid and to investigate the ability of Mesenchymal Stromal Cells (MSCs) to incorporate and release Pt-8AQ in its active form. The MSCs were primed with Pt-8AQ under optimized conditions and the secretome was analyzed for evaluating the cytotoxic activity of Pt-8AQ and the presence of Extracellular Vesicles (Evs). The principal results showed that Pt-8AQ incorporated by MSCs was released in the secretome and exerted a significant higher anticancer activity with respect to the free drug. The release of Pt-8AQ did not occur in Evs, as demonstrated for other drugs, but it could be delivered bound to some specific carriers able to enhance its bioavailability and efficacy. Some hypotheses are discussed to explain this surprisingly finding out that, however, it needs more investigations. The major conclusions are that cell mediated drug delivery systems could provide a potential approach to facilitate the GBM therapy by intra-tumoral administration of cells loaded with Pt-8AQ, being MSCs able to integrate it into the tumor mass and exert high therapeutic efficacy in situ. The increased efficacy of Pt-8AQ delivered by MSCs even suggests to deeper investigate a possible direct use of MSCs secretome both in situ and/or by systemic administration, being secretome able to pass the blood–brain tumor.
{"title":"Anticancer platinum-drug delivered by mesenchymal stromal cells improves its activity on glioblastoma","authors":"Valentina Coccè, Eleonora Martegani, Luisa Doneda, Isabella Rimoldi, Giorgio Facchetti, Coffetti Giulia, Giorgio Lucchini, Leda Roncoroni, Aldo Giannì, Costantino Corradini, Giulio Alessandri, Emilio Ciusani, Francesco Cilurzo, Silvia Franzè, Francesca Paino, Augusto Pessina","doi":"10.1186/s12645-023-00242-2","DOIUrl":"https://doi.org/10.1186/s12645-023-00242-2","url":null,"abstract":"Glioblastoma multiforme (GBM) is nowadays the most aggressive tumor affecting brain in adults with a very poor prognosis due to the limited therapies and the systemic cytotoxicity. Among the different new drugs, recently has been reported the in vitro anti-glioma activity of a new cationic platinum(II) complex bearing 8-aminoquinoline as chelating ligand (Pt-8AQ). The purpose of this research work was to confirm the activity of Pt-8AQ on U87-GM spheroid and to investigate the ability of Mesenchymal Stromal Cells (MSCs) to incorporate and release Pt-8AQ in its active form. The MSCs were primed with Pt-8AQ under optimized conditions and the secretome was analyzed for evaluating the cytotoxic activity of Pt-8AQ and the presence of Extracellular Vesicles (Evs). The principal results showed that Pt-8AQ incorporated by MSCs was released in the secretome and exerted a significant higher anticancer activity with respect to the free drug. The release of Pt-8AQ did not occur in Evs, as demonstrated for other drugs, but it could be delivered bound to some specific carriers able to enhance its bioavailability and efficacy. Some hypotheses are discussed to explain this surprisingly finding out that, however, it needs more investigations. The major conclusions are that cell mediated drug delivery systems could provide a potential approach to facilitate the GBM therapy by intra-tumoral administration of cells loaded with Pt-8AQ, being MSCs able to integrate it into the tumor mass and exert high therapeutic efficacy in situ. The increased efficacy of Pt-8AQ delivered by MSCs even suggests to deeper investigate a possible direct use of MSCs secretome both in situ and/or by systemic administration, being secretome able to pass the blood–brain tumor.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"147 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139414617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-06DOI: 10.1186/s12645-023-00239-x
Qiping Jiang, Fengjiao Yao, Yacong An, Xialian Lai, Xundou Li, Zhen Yu, Xian-Da Yang
PD-1/PD-L1 blockade plays a crucial role in cancer immunotherapy. Exploration of new technologies to further enhance the efficacy of PD-1/PD-L1 blockade is therefore of potential medical importance. Nanotherapeutics can accumulate in tumor tissues due to enhanced permeability and retention (EPR) effects. In this study, a novel nanotherapeutic for cancer immunotherapy was implemented with albumin nanoparticles functionalized by both PD-1 and PD-L1 aptamers. Albumin nanoparticles (NP) were functionalized with either PD-1 aptamers (PD1-NP), PD-L1 aptamers (PDL1-NP), or both types of aptamers (PD1-NP-PDL1). Average sizes of PD1-NP, PDL1-NP, and PD1-NP-PDL1 were 141.8 nm, 141.8 nm, and 164.2 nm, respectively. PD1-NP had good affinity for activated T cells that expresses PD-1. Similarly, PDL1-NP could bind with MDA-MB-231 or CT26 tumor cells that express PD-L1. Moreover, the bispecific PD1-NP-PDL1 could bind with both the activated T cells and the PD-L1-expressing tumor cells, and tether the two type of cells together. Functionally, aptamer-modified nanoparticles exhibited stronger immune-stimulating effects vs. free aptamers. Specifically, PD1-NP or PDL1-NP induced stronger lymphocyte-mediated cytotoxicity against PD-L1-expressing tumor cells in vitro vs. free PD-1 or PD-L1 aptamers. Animal studies also showed that PD1-NP or PDL1-NP significantly improved antitumor efficacy against CT26 colon cancer in vivo vs. free PD-1 or PD-L1 aptamers. Importantly, the bispecific PD1-NP-PDL1 further boosted the in vivo antitumor efficacy compared with PD1-NP or PDL1-NP, without raising systemic toxicity. The results suggest that the bispecific PD1-NP-PDL1 is a promising nanotherapeutic to improve the efficacy of PD-1/PD-L1 blockade, and may have application potential in colon cancer treatment.
{"title":"Novel nanotherapeutics for cancer immunotherapy by albumin nanoparticles functionalized with PD-1 and PD-L1 aptamers","authors":"Qiping Jiang, Fengjiao Yao, Yacong An, Xialian Lai, Xundou Li, Zhen Yu, Xian-Da Yang","doi":"10.1186/s12645-023-00239-x","DOIUrl":"https://doi.org/10.1186/s12645-023-00239-x","url":null,"abstract":"PD-1/PD-L1 blockade plays a crucial role in cancer immunotherapy. Exploration of new technologies to further enhance the efficacy of PD-1/PD-L1 blockade is therefore of potential medical importance. Nanotherapeutics can accumulate in tumor tissues due to enhanced permeability and retention (EPR) effects. In this study, a novel nanotherapeutic for cancer immunotherapy was implemented with albumin nanoparticles functionalized by both PD-1 and PD-L1 aptamers. Albumin nanoparticles (NP) were functionalized with either PD-1 aptamers (PD1-NP), PD-L1 aptamers (PDL1-NP), or both types of aptamers (PD1-NP-PDL1). Average sizes of PD1-NP, PDL1-NP, and PD1-NP-PDL1 were 141.8 nm, 141.8 nm, and 164.2 nm, respectively. PD1-NP had good affinity for activated T cells that expresses PD-1. Similarly, PDL1-NP could bind with MDA-MB-231 or CT26 tumor cells that express PD-L1. Moreover, the bispecific PD1-NP-PDL1 could bind with both the activated T cells and the PD-L1-expressing tumor cells, and tether the two type of cells together. Functionally, aptamer-modified nanoparticles exhibited stronger immune-stimulating effects vs. free aptamers. Specifically, PD1-NP or PDL1-NP induced stronger lymphocyte-mediated cytotoxicity against PD-L1-expressing tumor cells in vitro vs. free PD-1 or PD-L1 aptamers. Animal studies also showed that PD1-NP or PDL1-NP significantly improved antitumor efficacy against CT26 colon cancer in vivo vs. free PD-1 or PD-L1 aptamers. Importantly, the bispecific PD1-NP-PDL1 further boosted the in vivo antitumor efficacy compared with PD1-NP or PDL1-NP, without raising systemic toxicity. The results suggest that the bispecific PD1-NP-PDL1 is a promising nanotherapeutic to improve the efficacy of PD-1/PD-L1 blockade, and may have application potential in colon cancer treatment.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"11 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139374310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ovarian cancer treatment is challenged by resistance and off-target effects. Melittin shows promise against cancer but is limited by its instability and harmful cellular interactions. Our study introduces SiO2–alginate–melittin nano-conjugates (SAMNs), incorporating alginate lyase to enhance melittin's release and mitigate alginate drawbacks. We combined melittin with alginate and mesoporous silica, using alginate lyase to control melittin release. Effects on SKOV3 ovarian cancer cells were evaluated via viability, invasion, migration assays, ROS levels, apoptosis-related proteins, and mitochondrial function tests. SAMNs extended melittin’s cell control, reducing proliferation, invasion, and migration compared to free melittin. Alginate lyase facilitated controlled melittin release, decreasing off-target cytotoxicity. The only melittin group showed severe mitochondrial impairment, while the SAMNs and lyase groups had moderated impacts, indicating a dose-dependent effect on mitochondrial health and cell uptake. SAMNs, especially with alginate lyase, offer an effective strategy for ovarian cancer treatment, optimizing melittin delivery while minimizing adverse effects of alginate. This approach enhances the therapeutic potential of melittin in combating ovarian cancer.
{"title":"SiO2–alginate–melittin nano-conjugates suppress the proliferation of ovarian cancer cells: a controlled release approach leveraging alginate lyase","authors":"Lihui Si, Shuli Yang, Ruixin Lin, Shiyu Gu, Chuhan Yan, Jia Yan","doi":"10.1186/s12645-023-00241-3","DOIUrl":"https://doi.org/10.1186/s12645-023-00241-3","url":null,"abstract":"Ovarian cancer treatment is challenged by resistance and off-target effects. Melittin shows promise against cancer but is limited by its instability and harmful cellular interactions. Our study introduces SiO2–alginate–melittin nano-conjugates (SAMNs), incorporating alginate lyase to enhance melittin's release and mitigate alginate drawbacks. We combined melittin with alginate and mesoporous silica, using alginate lyase to control melittin release. Effects on SKOV3 ovarian cancer cells were evaluated via viability, invasion, migration assays, ROS levels, apoptosis-related proteins, and mitochondrial function tests. SAMNs extended melittin’s cell control, reducing proliferation, invasion, and migration compared to free melittin. Alginate lyase facilitated controlled melittin release, decreasing off-target cytotoxicity. The only melittin group showed severe mitochondrial impairment, while the SAMNs and lyase groups had moderated impacts, indicating a dose-dependent effect on mitochondrial health and cell uptake. SAMNs, especially with alginate lyase, offer an effective strategy for ovarian cancer treatment, optimizing melittin delivery while minimizing adverse effects of alginate. This approach enhances the therapeutic potential of melittin in combating ovarian cancer.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"13 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139374275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-06DOI: 10.1186/s12645-023-00243-1
Tutku Tunç
In recent studies with silver nanoparticles, it has been reported that the use of nanoparticles in carrier drug systems increases tumor suppression and reduces drug-related side effects. At the same time, the combination of traditional medicine with nanotechnology provides the opportunity to develop new antimicrobial agents. The aim of this study was to determine the anticancer, antimicrobial activities and pro-apoptotic effects of silver nanoparticles (AgNPs), and carboplatin-loaded silver nanoparticles (AgNPs-Car). Characterization studies of the synthesized nanoparticles were carried out by DLS, EDX-STEM, and FTIR analysis. The antiproliferative and pro-apoptotic effects of these molecules were evaluated using XTT and Annexin V, respectively. MIC (Minimum Inhibitory Concentration) test was used to determine the antimicrobial activity. The anticancer activity of the AgNPs-Car was high in MCF-7 (human breast adenocarcinoma), A549 (human lung carcinoma), and C6 (brain glioma) cells. The cell group with the most effective selective cytotoxic activity was C6 cells. It was also shown that AgNPs-Car and AgNPs induced DNA fragmentation eventually increasing apoptosis of cells. The antimicrobial activity of AgNPs and AgNPs-Car was evaluated on Gram-positive and Gram-negative pathogenic microorganisms and yeast fungi. Among the nanomaterials that reached effective MIC values according to reference sources, AgNPs-Car achieved better results. As a result, AgNPs-Car was found to be very successful in targeting C6 glioma cells by facilitating cell entry of the drug. In addition, their anticancer activity on MCF-7 and A549 cells was high and their toxicity was low. Silver nanoparticles are preferred for creating a better drug carrier system because of their qualitative properties and effects. Therefore, it is an interesting field for research on targeting cancer cells and pathogenic microorganisms.
{"title":"Synthesis and characterization of silver nanoparticles loaded with carboplatin as a potential antimicrobial and cancer therapy","authors":"Tutku Tunç","doi":"10.1186/s12645-023-00243-1","DOIUrl":"https://doi.org/10.1186/s12645-023-00243-1","url":null,"abstract":"In recent studies with silver nanoparticles, it has been reported that the use of nanoparticles in carrier drug systems increases tumor suppression and reduces drug-related side effects. At the same time, the combination of traditional medicine with nanotechnology provides the opportunity to develop new antimicrobial agents. The aim of this study was to determine the anticancer, antimicrobial activities and pro-apoptotic effects of silver nanoparticles (AgNPs), and carboplatin-loaded silver nanoparticles (AgNPs-Car). Characterization studies of the synthesized nanoparticles were carried out by DLS, EDX-STEM, and FTIR analysis. The antiproliferative and pro-apoptotic effects of these molecules were evaluated using XTT and Annexin V, respectively. MIC (Minimum Inhibitory Concentration) test was used to determine the antimicrobial activity. The anticancer activity of the AgNPs-Car was high in MCF-7 (human breast adenocarcinoma), A549 (human lung carcinoma), and C6 (brain glioma) cells. The cell group with the most effective selective cytotoxic activity was C6 cells. It was also shown that AgNPs-Car and AgNPs induced DNA fragmentation eventually increasing apoptosis of cells. The antimicrobial activity of AgNPs and AgNPs-Car was evaluated on Gram-positive and Gram-negative pathogenic microorganisms and yeast fungi. Among the nanomaterials that reached effective MIC values according to reference sources, AgNPs-Car achieved better results. As a result, AgNPs-Car was found to be very successful in targeting C6 glioma cells by facilitating cell entry of the drug. In addition, their anticancer activity on MCF-7 and A549 cells was high and their toxicity was low. Silver nanoparticles are preferred for creating a better drug carrier system because of their qualitative properties and effects. Therefore, it is an interesting field for research on targeting cancer cells and pathogenic microorganisms.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"15 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139374277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-05DOI: 10.1186/s12645-023-00238-y
Yilong Huang, Shasha Shen, Jie Xiao, Cici Luo, Jiyao Ma, Xin Huang, Tianfu Qi, Chao Gao, Guiyun Li, Fan Li, Bo He, Bingdi Chen, Dan Han
Mesothelin (MSLN) has been implicated in cancer migration, invasion, and prognosis, making it a potential tumor marker. However, the precise role of MSLN in the migration and invasion of malignant pleural mesothelioma (MPM) remains elusive, and effective noninvasive methods for assessing MSLN status are currently lacking. In this study, we focused on MSLN expression and elucidated the underlying mechanisms by which MSLN regulates migration and invasion in MPM. Building upon this knowledge, we developed an MRI nanoprobe that targets MSLN to assess its status in vitro and in vivo by comparing T2 signal intensity and T2 values on magnetic resonance imaging examinations. This nanoprobe combines the anatomical information obtained from MRI with biological information obtained from MSLN for comprehensive evaluation of MPM. Notably, we observed that MSLN expression in the epithelial type of MPM was higher and increased continuously with tumor growth than that in other types. In addition, MSLN upregulation promoted N-cadherin, matrix metalloproteinase-7, and MMP9 expression and resulted in higher migration/invasion ability and shorter survival. We synthesized MSLN-targeted nanoprobes (Fe3O4@SiO2-PEG-MSLN, FSPM) to assess MSLN expression by comparing the T2 signal intensity and T2 value of different cell lines and mice after 14, 28, and 42 days of modeling. Remarkably, MSLN-targeted nanoprobes demonstrated excellent targeting capabilities. In vitro studies revealed a pronounced reduction in T2 signal intensity and T2 values of the epithelial type as the probe concentration increased. In addition, in vivo experiments demonstrated a gradual decline in these parameters over time, particularly in the epithelial type as compared to the biphasic type, corresponding to the dynamic expression patterns of MSLN during different growth stages. Our comprehensive research succeeded in confirming the regulatory mechanisms by which MSLN influences migration and invasion. Moreover, we introduced a promising method for monitoring MSLN expression that may help in facilitating the early detection, histological subtype identification, and assessment of migration, invasion, and prognosis in MPM.
{"title":"Mesothelin-targeted MRI for assessing migration, invasion, and prognosis in malignant pleural mesothelioma","authors":"Yilong Huang, Shasha Shen, Jie Xiao, Cici Luo, Jiyao Ma, Xin Huang, Tianfu Qi, Chao Gao, Guiyun Li, Fan Li, Bo He, Bingdi Chen, Dan Han","doi":"10.1186/s12645-023-00238-y","DOIUrl":"https://doi.org/10.1186/s12645-023-00238-y","url":null,"abstract":"Mesothelin (MSLN) has been implicated in cancer migration, invasion, and prognosis, making it a potential tumor marker. However, the precise role of MSLN in the migration and invasion of malignant pleural mesothelioma (MPM) remains elusive, and effective noninvasive methods for assessing MSLN status are currently lacking. In this study, we focused on MSLN expression and elucidated the underlying mechanisms by which MSLN regulates migration and invasion in MPM. Building upon this knowledge, we developed an MRI nanoprobe that targets MSLN to assess its status in vitro and in vivo by comparing T2 signal intensity and T2 values on magnetic resonance imaging examinations. This nanoprobe combines the anatomical information obtained from MRI with biological information obtained from MSLN for comprehensive evaluation of MPM. Notably, we observed that MSLN expression in the epithelial type of MPM was higher and increased continuously with tumor growth than that in other types. In addition, MSLN upregulation promoted N-cadherin, matrix metalloproteinase-7, and MMP9 expression and resulted in higher migration/invasion ability and shorter survival. We synthesized MSLN-targeted nanoprobes (Fe3O4@SiO2-PEG-MSLN, FSPM) to assess MSLN expression by comparing the T2 signal intensity and T2 value of different cell lines and mice after 14, 28, and 42 days of modeling. Remarkably, MSLN-targeted nanoprobes demonstrated excellent targeting capabilities. In vitro studies revealed a pronounced reduction in T2 signal intensity and T2 values of the epithelial type as the probe concentration increased. In addition, in vivo experiments demonstrated a gradual decline in these parameters over time, particularly in the epithelial type as compared to the biphasic type, corresponding to the dynamic expression patterns of MSLN during different growth stages. Our comprehensive research succeeded in confirming the regulatory mechanisms by which MSLN influences migration and invasion. Moreover, we introduced a promising method for monitoring MSLN expression that may help in facilitating the early detection, histological subtype identification, and assessment of migration, invasion, and prognosis in MPM.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"18 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139103063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-30DOI: 10.1186/s12645-023-00235-1
Pramod C. Mane, Deepali D. Kadam, Ashok N. Khadse, Aditya R. Chaudhari, Supriya P. Ughade, Sachin B. Agawane, Ravindra D. Chaudhari
<p><b>Publisher Correction: Cancer Nanotechnol (2023) 14:79 </b><b>https://doi.org/10.1186/s12645-023-00226-2</b></p><p>The publisher regrets that the article was originally published without identifying Sachin Agawane as co-corresponding author of the article. This information has now been corrected through the correction article.</p><p>The Original article (Mane et al. 2023) has now been corrected.</p><ul data-track-component="outbound reference"><li><p>Mane PC, Kadam DD, Khadse AN, Chaudhari AR, Ughade SP, Agawane SB, Chaudhari RD (2023) Green adeptness in synthesis of non-toxic copper and cobalt oxide nanocomposites with multifaceted bioactivities. Cancer Nanotechnol 14:79. https://doi.org/10.1186/s12645-023-00226-2</p><p>Article CAS Google Scholar </p></li></ul><p>Download references<svg aria-hidden="true" focusable="false" height="16" role="img" width="16"><use xlink:href="#icon-eds-i-download-medium" xmlns:xlink="http://www.w3.org/1999/xlink"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Department of Zoology and Research Centre, Shri Shiv Chhatrapati College, Pune, Junnar, MH, 410502, India</p><p>Pramod C. Mane, Deepali D. Kadam, Ashok N. Khadse & Ravindra D. Chaudhari</p></li><li><p>Junnar, India</p><p>Aditya R. Chaudhari</p></li><li><p>Physical & Materials Chemistry Division, CSIR-National Chemical Laboratory, Pune, MH, 411008, India</p><p>Supriya P. Ughade</p></li><li><p>Academy of Scientific and Innovative Research (AcSIR), Sector 19, Kamla Nehru Nagar, Ghaziabad, UP, 201002, India</p><p>Supriya P. Ughade & Sachin B. Agawane</p></li><li><p>Biochemical Sciences Division, CSIR-National Chemical Laboratory, Pune, MH, 411008, India</p><p>Sachin B. Agawane</p></li></ol><span>Authors</span><ol><li><span>Pramod C. Mane</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Deepali D. Kadam</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Ashok N. Khadse</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Aditya R. Chaudhari</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Supriya P. Ughade</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Sachin B. Agawane</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Ravindra D. Chaudhari</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li></ol><h3>Corresponding authors</h3><p>Correspondence to Sachin B. Agawane or Ravindra D. Chaudhari.</p><h3>Publisher's Note</h3><p>Springer Nature remain
出版商更正:Cancer nanotechnology (2023) 14:79 https://doi.org/10.1186/s12645-023-00226-2The出版商很抱歉，这篇文章最初发表时没有指明Sachin Agawane是文章的共同通讯作者。此信息现已通过更正文章更正。原文(Mane et al. 2023)现已更正。张建军，张建军，张建军，张建军，张建军。纳米氧化铜纳米复合材料的制备及其生物活性研究。(2009)纳米氧化铜纳米复合材料的制备。癌症纳米技术14:79。https://doi.org/10.1186/s12645-023-00226-2Article中科院谷歌学者下载参考资料作者与单位印度贾纳邦浦那Shri Shiv Chhatrapati学院动物学系与研究中心，印度贾纳邦，410502 ramod C. Mane, Deepali D. Kadam, Ashok N. Khadse &;Ravindra D. ChaudhariJunnar，印度印度科学与创新研究学院(AcSIR) 19区，卡姆拉·尼赫鲁·纳加尔，加济阿巴德，北方邦，201002，印度科学与创新研究学院，csir -国家化学实验室，浦那，MH, 411008Sachin B. agawane生化科学部，csir -国家化学实验室，浦那，马来西亚，411008;IndiaSachin b AgawaneAuthorsPramod c ManeView publicationsYou作者也可以搜索PubMed的作者在谷歌ScholarDeepali d KadamView publicationsYou作者也可以搜索PubMed的作者在谷歌ScholarAshok n KhadseView publicationsYou作者也可以搜索PubMed的作者在谷歌ScholarAditya r . ChaudhariView publicationsYou作者也可以搜索PubMed的作者在谷歌ScholarSupriya p UghadeView publicationsYou也可以搜索这个作者作者在PubMed Google ScholarSachin B. AgawaneView作者出版物您也可以在PubMed Google ScholarSachin D. ChaudhariView作者出版物您也可以在PubMed Google ScholarSachin B. Agawane或Ravindra D. Chaudhari中搜索该作者。出版商声明:对于已出版的地图和机构关系中的管辖权要求，普林格·自然保持中立。开放获取本文遵循知识共享署名4.0国际许可协议，该协议允许以任何媒介或格式使用、共享、改编、分发和复制，只要您适当地注明原作者和来源，提供知识共享许可协议的链接，并注明是否进行了更改。本文中的图像或其他第三方材料包含在文章的知识共享许可协议中，除非在材料的署名中另有说明。如果材料未包含在文章的知识共享许可中，并且您的预期用途不被法律法规允许或超过允许的用途，您将需要直接获得版权所有者的许可。要查看本许可的副本，请访问http://creativecommons.org/licenses/by/4.0/。知识共享公共领域免责条款(http://creativecommons.org/publicdomain/zero/1.0/)适用于本文中提供的数据，除非在数据的署名中另有说明。转载和许可引用本文:mane, p.c.， Kadam, d.d.， Khadse, A.N.等。出版商更正:绿色熟练合成无毒铜和钴氧化物纳米复合材料与多方面的生物活性。中国生物医学工程学报，2014,32(2):444 - 444。https://doi.org/10.1186/s12645-023-00235-1Download引文发布:2023年11月30日doi: https://doi.org/10.1186/s12645-023-00235-1Share这篇文章任何你与以下链接分享的人都可以阅读到这篇文章:获得可共享的链接对不起，本文目前没有可共享的链接。复制到剪贴板由Springer Nature shareit内容共享计划提供
{"title":"Publisher Correction: Green adeptness in synthesis of non-toxic copper and cobalt oxide nanocomposites with multifaceted bioactivities","authors":"Pramod C. Mane, Deepali D. Kadam, Ashok N. Khadse, Aditya R. Chaudhari, Supriya P. Ughade, Sachin B. Agawane, Ravindra D. Chaudhari","doi":"10.1186/s12645-023-00235-1","DOIUrl":"https://doi.org/10.1186/s12645-023-00235-1","url":null,"abstract":"<p><b>Publisher Correction: Cancer Nanotechnol (2023) 14:79 </b><b>https://doi.org/10.1186/s12645-023-00226-2</b></p><p>The publisher regrets that the article was originally published without identifying Sachin Agawane as co-corresponding author of the article. This information has now been corrected through the correction article.</p><p>The Original article (Mane et al. 2023) has now been corrected.</p><ul data-track-component=\"outbound reference\"><li><p>Mane PC, Kadam DD, Khadse AN, Chaudhari AR, Ughade SP, Agawane SB, Chaudhari RD (2023) Green adeptness in synthesis of non-toxic copper and cobalt oxide nanocomposites with multifaceted bioactivities. Cancer Nanotechnol 14:79. https://doi.org/10.1186/s12645-023-00226-2</p><p>Article CAS Google Scholar </p></li></ul><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Department of Zoology and Research Centre, Shri Shiv Chhatrapati College, Pune, Junnar, MH, 410502, India</p><p>Pramod C. Mane, Deepali D. Kadam, Ashok N. Khadse & Ravindra D. Chaudhari</p></li><li><p>Junnar, India</p><p>Aditya R. Chaudhari</p></li><li><p>Physical & Materials Chemistry Division, CSIR-National Chemical Laboratory, Pune, MH, 411008, India</p><p>Supriya P. Ughade</p></li><li><p>Academy of Scientific and Innovative Research (AcSIR), Sector 19, Kamla Nehru Nagar, Ghaziabad, UP, 201002, India</p><p>Supriya P. Ughade & Sachin B. Agawane</p></li><li><p>Biochemical Sciences Division, CSIR-National Chemical Laboratory, Pune, MH, 411008, India</p><p>Sachin B. Agawane</p></li></ol><span>Authors</span><ol><li><span>Pramod C. Mane</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Deepali D. Kadam</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Ashok N. Khadse</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Aditya R. Chaudhari</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Supriya P. Ughade</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Sachin B. Agawane</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Ravindra D. Chaudhari</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li></ol><h3>Corresponding authors</h3><p>Correspondence to Sachin B. Agawane or Ravindra D. Chaudhari.</p><h3>Publisher's Note</h3><p>Springer Nature remain","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"40 4","pages":""},"PeriodicalIF":5.7,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138503621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：